Ticagrelor, Brillinta, is the newest antiplatelet agent on the market. Ticagrelor is a reversible nonthienopyridine P2Y12 receptor antagonist that prevents signal transduction and platelet activation.
Prasugrel, Effient, has a more rapid onset and better response than clopidogrel and is not affected by poor metabolizers or PPIs.

The standard-of-care for dual antiplatelet therapy (DAPT) for more than a decade has been clopidogrel (Plavix) plus aspirin. This standard is now being challenged by new agents — ticagrelor (Brilinta) and prasugrel (Effient). While the new agents are more effective at preventing platelet aggregation than clopidogrel, each has unique characteristics. Plavix went generic earlier this year, which may also impact decisions about which therapies to use. 

August 28, 2012 — Toshiba America Medical Systems Inc. has received U.S. Food and Drug Administration (FDA) clearance on its new Vantage Titan 1.5T series, which features the 8-, 16- and 32-channel MR (magnetic resonance) systems.

August 28, 2012 — The International Contrast Ultrasound Society (ICUS) applauded the U.S. Food and Drug Administration’s (FDA) decision to modify the U.S. product label for several ultrasound contrast agents used to improve the accuracy of radiation-free ultrasound scans.

August 28, 2012 — GE Healthcare announced important changes to the U.S. product label for Optison (perflutren protein-type A microspheres injectable suspension, USP), a contrast agent that may improve visualization of the left ventricular border, an area of the heart that is critical to see in order to diagnose certain heart diseases such as hypertrophic cardiomyopathy.

August 28, 2012 — NDS Surgical Imaging (NDSsi) is now shipping its new Dome GX4MP radiology display, a 30-inch widescreen model offering multimodality viewing in both color and grayscale.

Cardiac coronary calcium scoring.

August 27, 2012 — A recent multi-center study, led by researchers from Wake Forest School of Medicine and published in the Journal of the American Medical Association (JAMA) has indicated that computed tomography (CT) scanning of the heart and measuring the coronary artery calcium (CAC) score is the most accurate predictor of cardiovascular disease for individuals at intermediate risk for heart disease.

August 27, 2012 — Positron Corp., a molecular imaging healthcare company, announced the submission of a drug master file (DMF) with the U.S. Food and Drug Administration (FDA) for the production of active pharmaceutical ingredient- (API) grade strontium-82 through its wholly owned subsidiary, Manhattan Isotope Technology LLC (MIT).
meaningful use, Stage 2, cardiology, radiology, CPOE, clinical decision support

There are some key requirements specifically aimed at imaging and radiology included in the Stage 2 meaningful use requirements released Aug. 23 by the Department of Health and Human Services (HHS). HHS fielded many concerns and questions about these requirements and offered answers in the 642-page document.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now